Second-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity

Third-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity

First-generation cephalosporin antibiotic and interleukin 15 inhibitor, specifically interacting with interleukin 15 (IL-15) receptor subunit α (IL-15Rα) and to inhibit IL-15-dependent TNF-α and IL-17 synthesis, showing inhibitory activity against all of

Novel highly selective inhibitor of multidrug resistance protein 4 (MRP4)

Potent Antagonist for the Human Thyrotropin Receptor (TSHR)

Highly permeable non-Pglycoprotein substrate

Novel anti-hepatitis B virus (HBV) agent

Novel photoaffinity probe for cyclin-dependent kinase (CDK) family

Novel potent inhibitor of cyclin-dependent kinases (CDKs) 2, 5, and 9, displaying activities across more than 60 cancer cell lines

Potent and selective ATP competitiive inhibitor of cycB-CDK1, cycE-CDK2, and cycD1-CDK4

Novel inhibitor of the cyclin-dependent kinase 9 (CDK9)

Highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity

Novel potent dual inhibitor of CDK9 and BET proteins with balanced activities of BRD4 (IC50 = 12.7 nM) and CDK9 (IC50 = 22.4 nM), as well as good antiproliferative activities on a small cancer cell panel

Novel Potent and Selective CDK9 Degrader for Targeting Transcription Regulation in Triple-Negative Breast Cancer

Novel CDK8 inhibitor

Novel CDK8 inhibitor

Novel CDK8 inhibitor

Novel potent CDK8 inhibitor

Novel potent and highly selective CDK8 inhibitor, with no apparent potential for time-dependent CYP3A4 inhibition

Novel highly potent, selective, permeable CDK8 inhibitor

Novel inhibitor of CDK8

Novel potent and selective inhibitor of CDK8, also modulating CDK19

Potent dual inhibitor of CDK8/19, suppressing phosphorylated STAT1 in various cancer cells

Novel potent and selective dual inhibitor of CDK8 and CDK19

Novel potent CDK8 inhibitor

Novel potent and balanced dual CDK6/PIM1 inhibitor, showing high kinase selectivity and displaying stronger potency in reducing the burden of AML than palbociclib and SMI-4a in vivo

Novel potent CDK6 degrader

Potent, ATP-binding site-targeting Cdk4/D1 inhibitor

Novel potent and selective CDK12 inhibitor

Novel selective cdDHQD inhibitor